journal
MENU ▼
Read by QxMD icon Read
search

Translational Andrology and Urology

journal
https://www.readbyqxmd.com/read/30363524/entering-an-era-of-radiogenomics-in-prostate-cancer-risk-stratification
#1
REVIEW
Nachiketh Soodana-Prakash, Radka Stoyanova, Abhishek Bhat, Maria C Velasquez, Omer E Kineish, Alan Pollack, Dipen J Parekh, Sanoj Punnen
Radiogenomics is a field that amalgamates data from genomics and imaging techniques in order to derive clinically meaningful trends. In this article, we discuss the importance of prostate cancer risk classification and how data derived from genomic testing and multi-parametric magnetic resonance imaging (mpMRI) can be integrated into clinical decision-making processes with a focus on active surveillance (AS). Finally, we describe an ongoing prospective trial (Miami MAST trial) which incorporates imaging (mpMRI) and radiomics data in patients who are on AS for prostate cancer...
September 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30363516/nitrocellulose-tissue-prints-an-innovative-approach-to-preparing-high-quality-dna-and-rna-from-prostate-biopsies-without-compromising-the-cores-for-pathology-diagnosis
#2
Sandra M Gaston, William E Grizzle, Soroush Rais-Bahrami, Gary P Kearney
Much of the research that has been done on prostate cancer tissue biomarkers has relied on radical prostatectomies for biospecimens. However, it is well recognized that important groups of patients are under-represented or missing entirely from biorepository collections of radical prostatectomy specimens. Using prostate biopsy tissues for molecular biomarker research significantly expands the range of available patients to include men whose biopsies show no cancer as well as men who are treated non-surgically or who choose active surveillance...
September 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30363496/urinary-markers-aiding-in-the-detection-and-risk-stratification-of-prostate-cancer
#3
REVIEW
Nicholas Raja, Christopher M Russell, Arvin K George
The purpose of this review is to highlight the role of existing and promising urinary biomarkers for the detection and prognostication of prostate cancer (PCa). A number of novel urinary biomarkers have been introduced into the clinical space, which in combination with clinical variables, have demonstrated an increased ability to select patients for biopsy and identify men at risk of harboring clinically significant PCa. Though a number of assays require further validation, initial data is promising and forthcoming results will ultimately determine their clinical utility and commercial availability...
September 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30363494/mri-findings-guiding-selection-of-active-surveillance-for-prostate-cancer-a-review-of-emerging-evidence
#4
REVIEW
Zachary A Glaser, Kristin K Porter, John V Thomas, Jennifer B Gordetsky, Soroush Rais-Bahrami
Active surveillance (AS) for prostate cancer (PCa) is generally considered to be a safe strategy for men with low-risk, localized disease. However, as many as 1 in 4 patients may be incorrectly classified as AS-eligible using traditional inclusion criteria. The use of multiparametric magnetic resonance imaging (mpMRI) may offer improved risk stratification in both the initial diagnostic and disease monitoring setting. We performed a review of recently published studies to evaluate the utility of this imaging modality for this clinical setting...
September 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30363493/linking-cellular-metabolism-and-metabolomics-to-risk-stratification-of-prostate-cancer-clinical-aggressiveness-and-potential-therapeutic-pathways
#5
REVIEW
Eric Eidelman, Hemantkumar Tripathi, De-Xue Fu, M Minhaj Siddiqui
Prostate cancer treatment is based on the stratification of disease as low-, intermediate- or high-risk. This stratification has been largely based on anatomic pathology of the disease, as well as through the use of prostate specific antigen (PSA). However, despite this stratification, there remains heterogeneity within the current classification schema. Utilizing a metabolic approach may help to further establish novel biomolecular markers of disease aggressiveness. These markers may eventually be useful in not only the diagnosis of disease but in creating tumor specific targeted therapy for improved clinical outcomes...
September 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30363492/personalized-prostate-cancer-care
#6
Soroush Rais-Bahrami, Jennifer B Gordetsky
No abstract text is available yet for this article.
September 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30363486/optimizing-patient-selection-for-focal-therapy-mapping-and-ablating-the-index-lesion
#7
EDITORIAL
James S Wysock, Herbert Lepor
No abstract text is available yet for this article.
September 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30363485/ultra-small-superparamagnetic-iron-oxide-contrast-agents-for-lymph-node-staging-of-high-risk-prostate-cancer
#8
REVIEW
Marcin Czarniecki, Filippo Pesapane, Bradford J Wood, Peter L Choyke, Baris Turkbey
Ultrasmall superparamagnetic particles of iron oxide (USPIOs) imaged with magnetic resonance imaging (MRI) have been proposed as an experimental method for visualizing lymph node (LN) metastases. The method does not require ionizing radiation, yet can detect small nodes that are involved with metastases. USPIOs are naturally taken up by macrophages that deposit in the normal LN creating a low signal region in normal areas; areas within the node that do not show this loss of signal are likely involved by tumor although there can be other causes (fibrosis or inflammation)...
September 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30363480/rethinking-active-surveillance-for-prostate-cancer-in-african-american-men
#9
REVIEW
Gabriel Z Leinwand, Andrew T Gabrielson, Louis S Krane, Jonathan L Silberstein
Active surveillance (AS) is a treatment modality for prostate cancer that aims to simultaneously avoid overtreatment and allow for the timely intervention of localized disease. AS has become the de facto standard of care for most men with low-risk prostate cancer. However, few African American (AA) men were included in the prospective observational cohorts that resulted in a paradigm shift in treatment recommendations from active intervention toward AS. It has been established that AA men have an increased prostate cancer incidence, higher baseline prostate-specific antigen (PSA) values, more aggressive prostate cancer features, greater frequency of biochemical recurrence after treatment, and higher overall cancer-specific mortality compared to their Caucasian counterparts...
September 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30363476/improving-risk-stratification-in-a-community-based-african-american-population-using-cell-cycle-progression-score
#10
Walter Rayford, Mark Greenberger, Randy V Bradley
Background: Current clinical nomograms such as American Urological Association/National Comprehensive Cancer Network (AUA/NCCN) risk categories or CAPRA may not always reflect prostate cancer (PCa) risk among African American men. We evaluated the usefulness of adding a commercially available cell cycle progression (CCP) score to improve risk stratification in a community-based African American population. Methods: Biopsy tissues from 150 African American and 60 Caucasian men were obtained from a single community urologic oncology practice in Memphis, TN...
September 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30363475/role-of-pet-imaging-for-biochemical-recurrence-following-primary-treatment-for-prostate-cancer
#11
REVIEW
Samuel J Galgano, Roberto Valentin, Jonathan McConathy
Prostate cancer is one of the most common cancers in men worldwide, and primary prostate cancer is typically treated with surgery, radiation, androgen deprivation, or a combination of these therapeutic modalities. Despite technical advances, approximately 30% of men will experience biochemical recurrent within 10 years of definitive treatment. Upon detection of a rise in serum prostate specific antigen (PSA), there is great need to accurately stage these patients to help guide further therapy. As a result, there are considerable efforts underway to establish the role of positron emission tomography (PET) in the diagnostic algorithm of biochemically recurrent prostate cancer...
September 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30363470/developing-a-personalized-template-for-lymph-node-dissection-during-radical-prostatectomy
#12
REVIEW
Ram A Pathak, Ashok K Hemal
Lymph node dissection (LND) represents a critical step in order to determine lymph node invasion (LNI), not only for prognostic means but also as a therapeutic strategy in the management of patients with prostate cancer (CaP). Indications for performing LND are inconsistent with the American Urologic Association (AUA), European Association of Urology (EAU), and National Comprehensive Cancer Network (NCCN) recommendations differing. A thorough appreciation of lymph node drainage patterns and extent of LND has reshaped our understanding of this disease...
September 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30363466/detection-of-extraprostatic-disease-and-seminal-vesicle-invasion-in-patients-undergoing-magnetic-resonance-imaging-targeted-prostate-biopsies
#13
Erin M Baumgartner, Kristin K Porter, Jeffrey W Nix, Soroush Rais-Bahrami, Jennifer B Gordetsky
Background: Finding incidental extraprostatic extension (EPE) or seminal vesicle invasion (SVI) by prostate cancer (PCa) is rare on standard prostate biopsy. We evaluated the clinical-pathologic features associated with EPE and SVI on multiparametric magnetic resonance imaging (MRI)/ultrasound (US) fusion-guided targeted biopsy (TB). Methods: A retrospective review was performed from 2014-2017, selecting patients who had undergone TB. Clinical, pathologic, and radiologic features were evaluated...
September 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30363462/prostate-imaging-features-that-indicate-benign-or-malignant-pathology-on-biopsy
#14
REVIEW
Catherine Elizabeth Lovegrove, Mudit Matanhelia, Jagpal Randeva, David Eldred-Evans, Henry Tam, Saiful Miah, Mathias Winkler, Hashim U Ahmed, Taimur T Shah
Accurate diagnosis of clinically significant prostate cancer is essential in identifying patients who should be offered treatment with curative intent. Modifications to the Gleason grading system in recent years show that accurate grading and reporting at needle biopsy can improve identification of clinically significant prostate cancers. Extracapsular extension of prostate cancer has been demonstrated to be an adverse prognostic factor with greater risk of metastatic spread than organ-confined disease. Tumor volume may be an independent prognostic factor and should be considered in conjunction with other factors...
September 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30363452/clinical-significance-of-subtypes-of-gleason-pattern-4-prostate-cancer
#15
REVIEW
Oudai Hassan, Andres Matoso
Major updates in prostate cancer grading have been adopted in recent times. These include redefinitions of Gleason pattern (GP) 4 architectural variants and reporting of the grade group (GG) system, which divides prostate cancer into five groups that better stratify patients. Still, the GG system uses the GPs 3, 4 or 5 to define each GG. Patients belonging to GG 2, 3 and 4 have increasing amounts of GP 4 in the composition of their tumors. GP4 is a heterogeneous group of morphologic variants that include poorly formed glands, glomeruloid structures, cribriform glands, and fused glands...
September 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30363448/emerging-role-of-cytoreductive-prostatectomy-in-patients-with-metastatic-disease
#16
REVIEW
Yasmeen Jaber, Chad A Reichard, Brian F Chapin
Traditionally, systemic androgen deprivation therapy (ADT) has been the primary treatment modality in metastatic prostate cancer (mPCa) while treatment of the primary tumor has been reserved for patients with clinically localized disease. Emerging data suggests that treating the primary tumor in patients with metastatic disease may provide a survival benefit. However, these studies are fraught with selection bias towards patients with favorable disease characteristics. Despite these limitations, clinicians are becoming increasingly interested in consolidative treatment of the primary tumor in this setting...
September 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30363387/percent-gleason-pattern-4-in-stratifying-the-prognosis-of-patients-with-intermediate-risk-prostate-cancer
#17
REVIEW
Meenal Sharma, Hiroshi Miyamoto
The Gleason score remains the most reliable prognosticator in men with prostate cancer. One of the recent important modifications in the Gleason grading system recommended from the International Society of Urological Pathology consensus conference is recording the percentage of Gleason pattern 4 in the pathology reports of prostate needle biopsy and radical prostatectomy cases with Gleason score 7 prostatic adenocarcinoma. Limited data have indeed suggested that the percent Gleason pattern 4 contributes to stratifying the prognosis of patients who undergo radical prostatectomy...
September 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30211073/erratum-to-expanded-criteria-for-active-surveillance-in-prostate-cancer-a-review-of-the-current-data
#18
Cameron Jones, Mina M Fam, Benjamin J Davies
[This corrects the article DOI: 10.21037/tau.2017.08.23.].
August 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30211072/stage-t1-bladder-cancer-historic-background-and-latest-tracks-for-its-demystification
#19
EDITORIAL
Wolfgang Otto
No abstract text is available yet for this article.
August 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/30211071/refining-the-use-of-neoadjuvant-chemotherapy-in-locally-advanced-bladder-cancer-from-conviction-to-optimization
#20
EDITORIAL
St├ęphane Culine, Yves Allory, Christian Pfister
No abstract text is available yet for this article.
August 2018: Translational Andrology and Urology
journal
journal
44016
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"